744MO AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC)
| Autor: | Lee, J-Y. 1, Wu, L. 2, Boonyapipat, S. 3, Kim, H.S. 4, Lee, J-W. 5, Wang, L. 6, Wang, T. 7, Wang, D. 8, Yao, D. 9, Liu, H. 10, Andabekov, T. 11, Zhang, X. 12, Wang, W. 13, Kim, Y.M. 14, Wang, K. 15, Gao, Y. 15, Mu, X. 16, Volodymyrovych Sinielnikov, I. 17 |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S509-S510 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|